Abstract
Data in the scientific literature on the use of biologic therapy in localized forms of psoriasis elucidate mostly the problems of treatment of palmoplantar, scalp psoriasis and nail psoriasis. At the same time, the number of scientific data on the effect of biological therapy on genital psoriasis is extremely limited. Important that the quality of life on patients with genital psoriasis has very low level, which indicates a significant influence on the psychological and social well-being. At the same time, the limited number of therapeutic approaches makes this problem even more urgent. Unfortunately, special clinical trials for such patients are rather an exception. Ixekizumab has been reported an effectiveness for patients with anogenital psoriasis. New data on the comparative efficacy of ixekizumab and secukinumab give hope us for new opportunity for the treatment of genital psoriasis.
Highlights
Ixekizumab has been reported an effectiveness for patients with anogenital psoriasis
Sokolovskiy received fees and appeared as an expert/speaker/partaker in clinical trials and medical events sponsored by companies: Akrichin, Biocad, Amgen, Astellas, Avene, Bayer, Belupo, Bioderma, Celgene, CeraVe, Eli Lilly, Galderma, Glenmark, GSK, Janssen-Cilag, L’Oreal, La Roche-Posay, Leo Pharma, MSD, Novartis, Vichy, Uriage
Kokhan received fees and appeared as an expert/speaker/partaker in clinical trials and medical events sponsored by companies: Biocad, Vertex, SanFarma, AbbVie, Amgen, Bayer, Celgene, Eli Lilly, Galderma, JanssenCilag, Novartis
Summary
Новые данные по сравнительной эффективности иксекизумаба и секукинумаба вселяют надежду на новые возможности терапии псориаза половых органов. Соколовский получал гонорары и являлся консультантом/лектором/участником клинических исследований и мероприятий, спонсируемых компаниями: Акрихин, Биокад, Amgen, Astellas, Avene, Bayer, Belupo, Bioderma, Celgene, CeraVe, Eli Lilly, Galderma, Glenmark, GSK, Janssen-Cilag, L’Oreal, La RochePosay, Leo Pharma, MSD, Novartis, Vichy, Uriage.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.